Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$8.10 USD
-0.21 (-2.53%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $8.11 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.10 USD
-0.21 (-2.53%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $8.11 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Zacks News
Horizon (HZNP) Begins Phase IV Study on Tepezza for Chronic TED
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase IV study evaluating the safety and efficacy of Tepezza for the treatment of chronic (inactive) thyroid eye disease.
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
by Zacks Equity Research
Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.
Bayer's (BAYRY) Chronic Cough Candidate Meets Efficacy Goal
by Zacks Equity Research
Bayer (BAYRY) posts positive data from the phase IIb PAGANINI study which is evaluating its investigational candidate, eliapixant, in patients with refractory chronic cough.
Takeda (TAK) Hematology Candidate Fails in Late-Stage Study
by Zacks Equity Research
Takeda's (TAK) pipeline candidate, pevonedistat, fails to achieve statistically significant event-free survival in patients with hematological disorders.
Teva's (TEVA) NDA for Schizophrenia Drug Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Teva Pharmaceuticals (TEVA) and partner MedinCell's new drug application for risperidone, a potential treatment for schizophrenia.
Anixa (ANIX) Ovarian Cancer CAR-T Drug to Enter Clinical Study
by Zacks Equity Research
The FDA clears Anixa Biosciences' (ANIX) application to initiate clinical studies for its ovarian cancer CAR-T therapy. The stock rises following the announcement.
Amneal (AMRX) Parkinson's Candidate Successful in Pivotal Study
by Zacks Equity Research
Amneal's (AMRX) IPX-203 increases "Good On" time by 1.55 hours per dose versus immediate-release CD/LD in patients with Parkinson's disease.
Fibrogen (FGEN)/Astellas Get EU Nod for Roxadustat for Anemia
by Zacks Equity Research
Roxadustat, FibroGen (FGEN) and Astellas' candidate for symptomatic anemia of chronic kidney disease, secures EU approval. The drug is to be sold in Europe under the brand name Evrenzo.
Jazz's (JAZZ) Xywav Gets FDA Nod for Idiopathic Hypersomnia
by Zacks Equity Research
Jazz's (JAZZ) Xywav gets FDA approval for new indication, idiopathic hypersomnia. Following approval, Xywav becomes the first drug for treatment of this sleep disorder.
FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA
by Zacks Equity Research
NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.
5 High Earnings Yield Picks to Reap Handsome Rewards
by Rimmi Singhi
Invest in top-ranked high earnings yield stocks like DFIN, IRWD, LEN, EAT, SGH to strengthen your portfolio.
Jazz's (JAZZ) Epidyolex Gets Approval for New Indication in UK
by Zacks Equity Research
Jazz's (JAZZ) unit GW Pharmaceuticals' Epidyolex (cannabidiol) gets a regulatory nod for a new indication in the United Kingdom. Following this announcement, stock prices fell.
Reata (RETA) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Reata (RETA) beats estimates for earnings and sales. Stock down on negative regulatory update on lead pipeline candidate, bardoxolone.
Sanofi (SNY) Pompe Disease Drug Receives FDA's Approval
by Zacks Equity Research
The FDA gives approval to Sanofi's (SNY) Nexviazyme (avalglucosidase alfa) for treating late-onset Pompe disease.
Puma (PBYI) Q2 Loss Narrower Than Expected, Nerlynx View Cut
by Zacks Equity Research
Puma Biotech (PBYI) reports better-than-expected Q2 earnings and sales. It lowers 2021 Nerlynx sales guidance.
Ironwood's (IRWD) Q2 Earnings Beat, 2021 Guidance Raised
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the second quarter. Stock up.
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) earnings and revenues beat estimates in the second quarter of 2021. The company raised its financial guidance for 2021.
Aerie's(AERI) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Aerie (AERI) incurs wider-than-expected loss in the second quarter of 2021 but sales beat expectations.
Why Ironwood (IRWD) Could Beat Earnings Estimates Again
by Zacks Equity Research
Ironwood (IRWD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Athira (ATHA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus to be on the company's pipeline progress, mainly on its small molecule candidate ATH-1017 for Alzheimer's disease, on Athira's (ATHA) second-quarter earnings call.
Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.
Pacira's (PCRX) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings and revenues in the second quarter of 2021 surpass estimates. Exparel sales surge year over year.
Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout
by Zacks Equity Research
Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.
Esperion (ESPR) Q2 Loss Narrower Than Expected, Drug Price Up
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings but misses the same for sales. Stock down.
AMN Healthcare (AMN) to Report Q2 Earnings: What to Expect?
by Zacks Equity Research
Continued strength in AMN Healthcare's (AMN) staffing services is expected to have driven up Q2 sales.